Numinus Wellness Inc. (OTCMKTS:LKYSF) has announced expansion plans for its psychedelic research laboratory late this year. The company will add 7,500 sq. ft. of space, which will be developed in an existing leased building adjacent to Numinus’ current lab.
Numinus adding 7,500 sq. ft. to its research lab
This announcement comes days after the company received its federal license amendment under the Controlled Drugs and Substance ACT of Canada. The amendment permits the company to possess, produce, assemble, export, sales and deliver a range of psychedelics, including psilocybin, psilocin, Ketamine, LSD, N-Mtrthey-3,4, MDMA, Mescaline and N,N-Dimethyltryptamine (DMT).
Sharah Sidhu, Numinus Biosciences Scientific Officer and General Manager said that the company’s investment in an expanded lab is a massive milestone that offers the necessary foundation for necessary infrastructure for R&D of therapeutics advancing psychedelic-assisted psychotherapy. Sidhu added that once the lab is complete, it will enhance its partnerships strategy and IP and create more revenue via analytical psychedelics testing and contact services. Equally, the facility will enhance Numinus’ supply of safe, effective, and consistent psychedelics for trials and clinical use.
Numinus acquires Orbitrap to advance psychedelic research
Recently, the company acquired Orbitrap Exploris 120 mass spectrometer with Vanquish Flex Binary instrument for continued R&D for psilocybe mushroom projects at its 7,000 sq. ft. research and analytics lab. Orbitrap is an ultramodern high-resolution mass spectrometry instrument whose implementation will accelerate Numinus Bioscience’s research strategy to maximize cultivation, extraction, and harvest of psilocybe mushrooms. This comes at the back of its successful first legal extraction for R&D purposes in December last year.
Sidhu said that Numunus has continued to break R&D ground in psychedelic-assisted therapies, and Orbitrap’s implementation cements the company’s position as a psychedelics R&D center of excellence. Further, Sidhu said that since they are early psychedelics license holders, the announcement shows the company’s commitment to stay on top of psychedelic research. Most importantly, the acquisition of Orbitrap is a massive step in the path to developing the first patent to advance psilocybe mushroom-related psychedelic research.
